| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000031064 |
| Receipt No. | R000035417 |
| Official scientific title of the study | To investigate the effect of ripasudil hydrochloride hydrate eye drops for retinal vein occlusion(RVO) |
| Date of disclosure of the study information | 2018/02/01 |
| Last modified on | 2018/01/30 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | To investigate the effect of ripasudil hydrochloride hydrate eye drops for retinal vein occlusion(RVO) | |
| Title of the study (Brief title) | The effect of ripasudil eye drops for RVO | |
| Region |
|
|
| Condition | ||
| Condition | Retinal vein occlusion | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Among patients with both retinal vein occlusion and glaucoma, those who do not achieve complete regression of macula edema with anti-VEGF drugs or who need frequent injection of anti-VEGF drugs are enrolled in this study. We consider if the patients achieve complete regression of macula edema or need less injection of anti-VEGF drugs using ripasudil hydrochloride hydrate eye drops which is one of the ROCK inhibitor. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The change in central retinal thickness measured by optical coherence tomography before and 12 after the treatment |
| Key secondary outcomes | The frequency of intravitreal injection of anti-VEGF drugs |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of ripasudil eye drops twice a day for 12 months. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who have early glaucoma or ocular hypertension
Patients who do not have complete regression of macula edema with intravitreal injection of anti-VEGF drugs, or who need frequent injection of drugs to maintain the condition of complete disappearance of edema Patients aged 20 years and older at the time of informed consent Patients who gave written consent to study participation by free documentation and verbally enough explanation |
|||
| Key exclusion criteria | Patients with other ocular disorders
Patients with a bad control of intra ocular pressure Others who are deemed unsuitable for inclusion in the study for any other reason based on the assessment by the investigators |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Tsuyoshi Otsuji |
| Organization | Kansai Medical University Medical Center |
| Division name | Ophthalmology |
| Address | 10-15 Fumizonocho Moriguchi, Osaka |
| TEL | 06-6992-1001 |
| otsuji@takii.kmu.ac.jp | |
| Public contact | |
| Name of contact person | Tsuyoshi Otsuji |
| Organization | Kansai Medical University Medical Center |
| Division name | Ophthalmology |
| Address | 10-15 Fumizonocho Moriguchi, Osaka |
| TEL | 06-6992-1001 |
| Homepage URL | |
| otsuji@takii.kmu.ac.jp | |
| Sponsor | |
| Institute | Kansai Medical University Medical Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Self funding |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035417 |